Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]

  • In development
  • GID-TA11599
  • Expected publication date: 

Documents

Documents created during the development process.

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Referral

Topic selection